Microbiology Methods
Sputum specimens were transported via special couriers, maintaining cold chain, to the Edinburgh Central Microbiology Laboratory of Professor Govan, to be plated within 48 hours of obtaining specimen. A similar transportation mechanism was used for US specimens delivered to the Central Laboratory of Professor Jane Burns at Seattle Children's Hospital. A harmonized protocol (on file at Insmed) using methods previously described (Isenberg, Henry, D., Editor. aeruginosa identification, and quantitative methodology using serial dilutions and plating were employed. Specimens not meeting the criteria of minimum volume of 0.4ml and available at laboratory within 48h for culture were rejected.
Study design -open label extension
Following a review of the safety and pharmacokinetic data, an open label extension study of repeated Arikace® cycles was conducted at the European sites, utilizing a dosing schedule of 28 days of once daily Arikace® (560mg) followed by 56 days off treatment (six cycles). All subjects enrolled in the extension study had been enrolled in the 28d placebo-controlled trial (n=49).
Pharmacokinetic Analysis
Blood samples were collected predose, at 0-1h and 3-4h post dose on Day 1, and predose and at 0-1h post final dose on Day 28 to perform PK analysis. In addition, blood samples were taken on Day 35. Sputum samples were obtained one hour post dosing on Days 1, 14, and 28.
Concentrations of amikacin in serum were determined by a sensitive and specific liquid chromatography method with tandem mass spectrometry detection (LC-MS/MS) with a lower limit of quantification of 0.15mg/L and an inter-day CV% of <6.95%. Concentrations of amikacin in sputum were determined by a similar tandem mass spectrometry detection method (LC-MS/MS) with a lower limit of quantification of 0.1mg/L and an inter-day CV% of 8.6%. Concentrations in the sputum were then corrected based on the weight of the sample to obtain sputum concentrations in µg/g.
Statistical analysis.
The effect of Arikace® on lung function and P. aeruginosa sputum density were determined by repeated measures ANOVA. Analyses of the CFQ-R scales included calculating both the absolute (Study day value -Day 1 value) and relative changes; scores for each domain were summarized by visit. The absolute change in domain score was calculated between Days 1-15, 15-28, and 28-42, and then analyzed by ANCOVA. Day 1 (baseline) scores were used as the A responder analysis, categorizing patients into three groups based on the MID (improvedincrease >4 points; stable -change of <±4 points; worsened -decrease >4 points), was conducted using the relative change scores for each assessment period. Missing CFQ-R data from Day 28 (three Arikace® 560mg subjects, one placebo) were categorized as 'stable' relative to prior measurements. Treatment groups within each cohort were compared using chi-square tests. Additional supportive analyses included Pearson correlation coefficients between changes in CFQ-R Respiratory Symptoms and changes in FEV 1 % predicted from baseline values in the 560mg vs placebo groups.
Supplemental Results

Patient-Reported Outcomes
Results from the Respiratory domain of the CFQ-R indicated that at Day 28 of treatment, 24 (66.7%) of the 560mg dose group reported clinically significant improvements (MCID increase ≥4 points), compared to 13 (36.1%) of placebo-treated patients ( Figure S2 , P=0.006).
There were no significant differences observed in the lower Arikace® dose groups or in other CFQ-R domains (Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. 
Pharmacokinetic/Pharmacodynamic Results
Amikacin pharmacokinetics in sputum, serum, and urine are summarized here and in Table S3 . This data is presented as median (range) due to non-normal distribution. For the 560mg dose group, median sputum concentrations of amikacin 1h post-dosing (min, max) on 
Supplemental Tables
METABOLISM AND NUTRITION DISORDERS 0 (0.0%) 1 (20.0%) 0 (0.0%) 1 (2.8%) 1 (2.8%) DECREASED APPETITE 0 (0.0%) 1 (20.0%) 0 (0.0%) 1 (2.8%) 0 (0.0%) HYPERGLYCAEMIA 0 (0.0%) 1 (20.0%) 0 (0.0%) 0 (0.0%) 1 (2.8%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS
1 (14.3%) 0 (0.0%) 0 (0.0%) 6 (16.7%) 4 (11.1%) 
